Drug Type Biological products |
Synonyms- |
Target |
Mechanism GAGs inhibitors(glycosaminogycans inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 1 | NL | 01 Nov 2024 | |
Chondrosarcoma | Phase 1 | NL | 01 Nov 2024 | |
Colonic Cancer | Phase 1 | NL | 01 Nov 2024 | |
Esophageal Carcinoma | Phase 1 | NL | 01 Nov 2024 | |
Glioblastoma | Phase 1 | NL | 01 Nov 2024 | |
Lung Cancer | Phase 1 | NL | 01 Nov 2024 | |
Osteosarcoma | Phase 1 | NL | 01 Nov 2024 | |
Pancreatic Cancer | Phase 1 | NL | 01 Nov 2024 | |
Rectal Cancer | Phase 1 | NL | 01 Nov 2024 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | NL | 01 Nov 2024 |